|
BRD4 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 7.86960496768074E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
7.3671000411224E-09 |
| Normal-vs-Stage2 |
1.573130E-04 |
| Normal-vs-Stage3 |
1.05779995873689E-09 |
| Normal-vs-Stage4 |
2.53209999967474E-07 |
| Stage1-vs-Stage2 |
4.898400E-01 |
| Stage1-vs-Stage3 |
1.056210E-01 |
| Stage1-vs-Stage4 |
4.766200E-01 |
| Stage2-vs-Stage3 |
7.993600E-02 |
| Stage2-vs-Stage4 |
2.524800E-01 |
| Stage3-vs-Stage4 |
5.398000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.35499977694087E-10 |
| Normal-vs-AfricanAmerican |
9.344400E-03 |
| Normal-vs-Asian |
4.40209999996721E-06 |
| Caucasian-vs-AfricanAmerican |
2.357400E-01 |
| Caucasian-vs-Asian |
9.085800E-01 |
| AfricanAmerican-vs-Asian |
3.226000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.90829996038877E-09 |
| Normal-vs-Female |
4.68419969479328E-10 |
| Male-vs-Female |
5.129400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.43460000048934E-07 |
| Normal-vs-Age(41-60Yrs) |
1.24339982754407E-10 |
| Normal-vs-Age(61-80Yrs) |
1.27350000544979E-08 |
| Normal-vs-Age(81-100Yrs) |
3.961800E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.075600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.207600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.331200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.887000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.536200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.793400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.595600E-03 |
| Classical-VS-Follicular |
7.943800E-03 |
| Classical-VS-Other |
1.389380E-01 |
| Classical-VS-Normal |
5.43839999700424E-08 |
| Tall-VS-Follicular |
4.130800E-01 |
| Tall-VS-Other |
9.070000E-01 |
| Tall-VS-Normal |
1.35080000518428E-08 |
| Follicular-VS-Other |
5.906000E-01 |
| Follicular-VS-Normal |
4.72829997377744E-09 |
| Other-VS-Normal |
2.355600E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.95080004875103E-09 |
| Normal-vs-N1 |
2.97810000005061E-06 |
| N0-vs-N1 |
8.578600E-01 |
|
|
